Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Acorda Therapeutics Inc | ACOR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.661 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 0.6116 - 24.196 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 0.661 | USD |
Acorda Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 821.03k | - | - | - | -0.38 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Acorda Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACOR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 13.74 | 13.74 | 0.6116 | 1.86 | 845,926 | -13.08 | -95.19% |
3 Months | 15.85 | 16.73 | 0.6116 | 2.06 | 161,423 | -15.19 | -95.83% |
6 Months | 10.01 | 18.00 | 0.6116 | 2.48 | 69,938 | -9.35 | -93.40% |
1 Year | 9.60 | 24.196 | 0.6116 | 15.12 | 249,001 | -8.94 | -93.11% |
3 Years | 94.00 | 127.20 | 0.6116 | 27.21 | 718,293 | -93.34 | -99.30% |
5 Years | 1,338.00 | 1,458.00 | 0.6116 | 143.54 | 1,353,310 | -1,337.34 | -99.95% |
Acorda Therapeutics Description
Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States. |